 |
|
Confronting the challenge of antimicrobial resistance
March 11, 2008NIAID describes research efforts aimed at reducing antimicrobial resistance
Drug resistance is making many diseases increasingly difficult--and sometimes impossible--to treat, according to Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. "Extensively drug-resistant tuberculosis and invasive methicillin-resistant Staphylococcus aureus (MRSA) infections are just two recent examples of this problem that pose serious threats to domestic and global health," he adds. In a new report in the Journal of Infectious Diseases, now available online, Dr. Fauci outlines NIAID's commitment to addressing this urgent public health issue.
NIAID is meeting the complex challenge of antimicrobial resistance through a multifaceted research approach that includes partnerships with other federal agencies, academia, industry and non-governmental organizations, the authors report. In fiscal year 2007, NIAID invested more than $800 million to support basic and translational research on antimicrobials, more than $200 million of which was devoted to understanding the causes, consequences and treatments of antimicrobial drug resistance.
Basic research projects under way at NIAID or in NIAID-supported labs across the country include the following:
* Investigations of mechanisms of resistance and how these traits are acquired and passed on by microbes
* Research on factors that contribute to the virulence of pathogens such as MRSA
* Efforts to better understand and ultimately prevent biofilms--slimy coatings made by communities of bacteria that are impervious to the effects of antibiotics
* Creation of computer-based virtual microbial metabolic pathways that allow quick identification of potential drug targets
Facilitating the translation of basic research findings into better diagnostics, new therapies and novel strategies to slow the emergence of antimicrobial resistance is also an area of emphasis for the Institute, write the authors. The following are examples of the many applied and translational research programs supported by NIAID:
* Numerous clinical trials, including is assessing the need for antibiotics in children with acute middle-ear infections; and two trials designed to test off-patent oral antibiotics for treating uncomplicated community-associated MRSA
* Preclinical development of vaccine candidates to prevent staphylococcal infections
* Efforts to improve diagnostics, particularly for healthcare-associated bacterial infections that are already or are likely to become drug-resistant, such as Clostridium difficile, Pseudomonas and Acinetobacter
* DNA sequencing and other genomics resources that aid in discovery of diagnostics and therapeutics
Finally, the authors outline several new and established NIAID partnerships addressing antimicrobial resistance, including
* The Federal Interagency Task Force on Antimicrobial Resistance, co-chaired by NIAID, the Centers for Disease Control and Prevention, and the Food and Drug Administration, which implements an annually updated action plan
* The international Lilly Not-For-Profit Partnership for TB Early Phase Drug Discovery, which integrates the expertise of the pharmaceutical industry with university-based researchers to develop new drugs against TB, including multidrug-resistant and extensively drug-resistant forms of TB
* A collaboration with the Novartis Institute for Tropical Diseases to advance new drugs to treat dengue fever
"With antimicrobial resistance, we face the perpetual challenge of maintaining a favorable balance between microbes and humans," says Dr. Fauci. "The efforts of NIAID and all our partners from the public health, research and pharmaceutical sectors are critical to addressing this challenge and thus keeping us at least one step ahead of our microbial foes."
NIH/National Institute of Allergy and Infectious Diseases
Antimicrobial Resistance Current Events and Antimicrobial Resistance News RSSU.S. and European Experts Applaud Creation of New Transatlantic Task Force on Global Antibiotic Resistance Threat
Experts on both sides of the Atlantic applaud President Barack Obama and Swedish Prime Minister Fredrik Reinfeldt, representing the European Union (EU) Presidency, for establishing a transatlantic task force to address antibiotic resistance, an urgent and growing problem that threatens patient safety and public health worldwide.
Paradigm shift needed to combat drug resistance
When people travel, bacteria and other infectious agents travel with them. As about a billion people cross international borders each year, many more billions of the bugs come along for the ride.
Typhoid fever cases in US linked to foreign travel
Infection with an antimicrobial-resistant strain of typhoid fever among patients in the United States is associated with international travel, especially to the Indian subcontinent (India, Pakistan, and Bangladesh).
UTSA biology researchers demystify elusive war zone bacterium
Tao Weitao, a researcher in the College of Sciences' Department of Biology at the University of Texas at San Antonio is making great strides in a project that was funded one year ago by the San Antonio Area Foundation.
Genes key to staph disease severity, drug resistance found hitchhiking together
Scientists studying Staphylococcus bacteria, including methicillin-resistant S. aureus (MRSA), have discovered a potent staph toxin responsible for disease severity.
Antibiotic resistant bacteria found in fertilizer
Vancomycin resistant enterococci (VRE) have been found in sewage sludge, a by-product of waste-water treatment frequently used as a fertilizer.
CDC analysis finds unique social and behavior intervention helps reduce MRSA rates up to 62 percent
he Robert Wood Johnson Foundation (RWJF) and the Plexus Institute (Plexus) today announce results from an analysis of a multifaceted methicillin-resistant Staphylococcus aureus (MRSA) prevention program that employed positive deviance (PD), a novel approach to social and behavioral change, to trigger significant reductions in MRSA incidence ranging from 26 to 62 percent at participating hospitals.
Antimicrobial resistance in clinics, hospitals and at home
Antibiotic resistance and the rise of illnesses that cannot be treated easily because of drug resistance is a health concern around the world. CMAJ launches a 6-part series on antibiotic resistance to provide practical treatment guidelines for practicing doctors to manage resistant microbes in 3 settings: the hospital, clinic and home.
European league-tables for antibiotic resistance revealed
Tests of antibiotic resistance in cattle have revealed stark variation across thirteen European countries. The results, published today in BioMed Central's open-access journal Acta Veterinaria Scandinavica, show that major differences were apparent in the occurrence of resistance between countries and between the different antimicrobial agents tested.
Cethromycin achieves all endpoints in second pivotal Phase III Trial for treatment for pneumonia
Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), today announced positive results from Trial CL-05, the second of two pivotal phase III clinical trials designed to assess the safety and effectiveness of cethromycin, a novel once-a-day oral antibiotic for the treatment of mild-to-moderate community acquired pneumonia (CAP), the sixth leading cause of death in the United States.
More Antimicrobial Resistance Current Events and Antimicrobial Resistance News Articles
 |
Antimicrobial Resistance: Problem Pathogens and Clinical Countermeasures (Infectious Disease and Therapy) by Robert C. Owens Jr. (Editor), Ebbing Lautenbach (Editor) This publication provides a state-of-the-art overview of key issues related to antimicrobial resistance, including a focus on key pathogens causing common healthcare-associated and community-acquired infections. The epidemiology and therapeutic considerations of these antimicrobial resistant organisms are discussed, as well as the clinical and health economic impact of infections caused by them. This progressive reference also provides a dedicated section covering the clinical programmatic strategies used to minimize the growing antimicrobial resistance problem, including practical information related to interventional concepts and their implementation. In addition to antimicrobial resistance in the context of traditionally discussed problematic bacterial pathogens, emerging data related... |
|
Battling Chronic Infections: A State of the Science Review of Antimicrobial Resistance in Biofilms CD-ROM Starring: Phil Stewart Directed By: Ryan Jordan | |
 |
Antimicrobial Resistance in Bacteria of Animal Origin by Frank M. Aarestrup (Editor) Antimicrobial Resistance in Bacteria of Animal Origin comprehensively examines the current research on antimicrobial resistance in the main veterinary and zoonotic pathogens, including resistance to disinfectants and metals used in agriculture. Providing a broad overview from a global perspective, this new volume is an important reference for students, researchers, public health experts, veterinarians, and anyone with an interest in resistant bacteria in animals. Written by experts in the field of antimicrobial resistance, the early chapters provide information on modes of action of antibiotics and mechanisms of bacterial resistance, in addition to exploring the history of antimicrobial use in agriculture. Several chapters are devoted to examination of antimicrobial resistance in... |
 |
Bacterial Resistance to Antimicrobials, Second Edition by Richard G. Wax (Editor), Kim Lewis (Editor), Abigail Salyers (Editor), Harry Taber (Editor) The enormous genetic flexibility of bacteria jeopardizes the usefulness of currently available antibiotics, and requires new approaches to antibiotic discovery and development. Antimicrobial resistance can be acquired in a short time frame, both by genetic mutation and by direct transfer of resistance genes across genus and species boundaries. Understanding mechanisms of resistance is crucial to the future of antimicrobial therapy. Extensively revised, with contributions from international leaders in their fields, Bacterial Resistance to Antimicrobials, Second Edition blends scientific and practical approaches to the social, economic, and medical issues related to this growing problem. The book begins with a history of antimicrobial agents and bacterial resistance, and outlines... |
 |
Antimicrobial Resistance and Implications for the 21st Century (Emerging Infectious Diseases of the 21st Century) by I.W. Fong (Editor), Karl Drlica (Editor) Antimicrobial resistance can develop in any type of microbe (germ). Microbes can develop resistance to specific medicines. A common misconception is that a person’s body becomes resistant to specific drugs. However, it is microbes, not people that become resistant to the drugs. Drug resistance happens when microbes develop ways to survive the use of medicines meant to kill or weaken them. If a microbe is resistant to many drugs, treating the infections it causes can become difficult or even impossible. Someone with an infection that is resistant to a certain medicine can pass that resistant infection to another person. In this way, a hard-to-treat illness can be spread from person to person. In some cases, the illness can lead to serious disability or even death. This... |
 |
Antimicrobial Drug Resistance: Mechanisms of Drug Resistance, Volume 1 (Infectious Disease) by Douglas L. Mayers (Editor) The volumes included in Antimicrobial Drug Resistance represent the first comprehensive, multidisciplinary reference covering the area of antimicrobial drug resistance in bacteria, fungi, viruses, and parasites from basic science, clinical, and epidemiological perspectives. The first volume, Antimicrobial Drug Resistance, Mechanisms of Drug Resistance, is dedicated to the biological basis of drug resistance and effective avenues for drug development. With the emergence of more drug-resistant strains, the approach to dealing with the drug resistance problem must include the research of different aspects of the mechanisms of bacterial resistance and the dissemination of resistance genes as well as research utilizing new genomic information. These approaches will permit the design... |
 |
Antimicrobial Resistance in Developing Countries (Emerging Infectious Diseases of the 21st Century) by Aníbal de J. Sosa (Editor), Denis K. Byarugaba (Editor), Carlos F. Amábile-Cuevas (Editor), Po-Ren Hsueh (Editor), Samuel Kariuki (Editor), Iruka N. Okeke (Editor) Today, there is considerable literature regarding the subject of antimicrobial resistance. However, most of this information is based on information from developed countries. Very little organized information is available about the subject that critically examines the problem in developing countries. Scattered literature is available in various forms in journals that are often not easily accessible to the affected developing countries. The objective of the book is to put together data and information about the problem of antimicrobial resistance in developing countries addressing the general global perspectives, the risk factors, the current rates, trends, and possibilities for containment as they relate to specific conditions in those developing countries. |
 |
Antimicrobial Resistance in Bacteria by Amabile-Cuevas (Author) Antimicrobial resistance in bacteria is increasing at an alarming rate and presents an enormous global health challenge. Multi-drug resistance in particular is a major problem and severely compromises our ability to deal with infectious disease. The cost of the problem in terms of money, mortality and disability is also rising. This book presents nine comprehensive and cutting-edge reviews on the current state of antimicrobial resistance. Special emphasis is placed on state-of-the-art research and the authors focus on novel approaches and new perspectives. Topics covered include new antibiotics, biofilm resistance, drug efflux, plasmid-mediated resistance, extended-spectrum beta-lactamases, monitoring of resistance, predicting the evolution of new resistance,... |
|
Antibiotics: Assessment of Antimicrobial Activity and Resistance (Technical Series (Society for Applied Bacteriology)) by A. Denver Russell (Editor) | |
 |
Frontiers in Antimicrobial Resistance: A Tribute to Stuart B. Levy by David G. White (Editor), Michael N. Alekshun (Editor), Patrick F. Mcdermott (Editor), Stuart B. Levy (Editor) "Frontiers in Antimicrobial Resistance: A Tribute to Stuart B. Levy" offers a unique examination of the state of antimicrobial and anticancer drug resistance. Written by acknowledged experts who have spent time in Dr. Levy's laboratory or who have otherwise collaborated with him professionally, this new volume is a tribute to Dr. Levy and acknowledges his significant contributions to the field. This work: offers a unique scope of coverage, integrating the latest science with public education programs to use antimicrobials appropriately; provides comprehensive and detailed coverage of the most current research on antimicrobial resistance; presents contributions from acknowledged experts in the field; covers the most important clinical pathogens and the major drug classes; addresses an... |
| © 2009 BrightSurf.com |